<DOC>
	<DOCNO>NCT01021852</DOCNO>
	<brief_summary>This cross-over , polysomnography ( PSG ) study test safety , tolerability effectiveness different dos MK-6096 treatment participant primary insomnia . The primary efficacy hypothesis least one dose MK-6096 superior placebo improve sleep efficiency ( SE ) measure PSG Night 1 end 4 week treatment ( Week 4 ) .</brief_summary>
	<brief_title>Polysomnography Study MK-6096 Participants With Primary Insomnia ( MK-6096-011 )</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Participant willing stay overnight sleep laboratory 6 separate night willing stay bed least 8 hour night sleep laboratory Participant 's regular bedtime 9 PM 12 AM ( midnight ) Participant able read complete questionnaire diary Participant willing refrain napping study If female , participant breast feeding , pregnant , plan become pregnant Participant expect donate egg sperm study Participant history neurological disorder Participant history within past 6 month cardiovascular disorder unstable angina , congestive heart failure acute coronary syndrome . Participant difficulty sleep due medical condition Participant donate blood product within 8 week prior study Participant plan travel across 3 time zone study Participant currently participate participate study investigational compound device within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>